Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | FER | P16591 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9360788 | 0.89 | PARP1 (0.49) | SLC22A12CCNCCDK8CCR1CCR5 | |
| SCHEMBL16248020 | 0.81 | CCNC (0.49) | SLC22A12CCNCCDK8KDRCNR1 | |
| SCHEMBL16289500 | 0.79 | CCNC (0.48) | SLC22A12CCNCCDK8KDRCNR1 | |
| SCHEMBL2326429 | 0.77 | CCR1 (0.50) | SLC22A12CCNCCDK8CCR1CCR5 | |
| SCHEMBL30050271 | 0.76 | CCNC (0.48) | SLC22A12CCNCCDK8KDRCNR1 | |
| Hydrochloric Acid SCHEMBL28643028 | 0.76 | CCR1 (0.48) | SLC22A12CCNCCDK8CCR1CCR5 | |
| SCHEMBL422643 | 0.76 | SMN1; SMN2 (0.59) | SLC22A12CCNCCDK8KDRCHEK1 | |
| SCHEMBL31510479 | 0.76 | CCNC (0.48) | SLC22A12CCNCCDK8KDRCNR1 | |
| SCHEMBL317086 | 0.76 | CCNC (0.48) | SLC22A12CCNCCDK8KDRCNR1 | |
| SCHEMBL8547469 | 0.76 | CCNC (0.48) | SLC22A12CCNCCDK8KDRCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
| US-5589484-A | TREATMENT OF HELICOBACTER INFECTIONS, ANTIULCER | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-12-31 | — | — | US | disclosed |
| EP-0666855-B1 | 4-QUINOLINYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 1996-09-18 | — | — | EP | disclosed |
| EP-0666855-A1 | 4-QUINOLINYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY. | JANSSEN PHARMACEUTICA NV (BE) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994010164-A1 | 4-QUINOLINYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | SLC22A12 3434/4885CCNC 738/4885CDK8 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.